| 1 | ANIFROLUMAB | [1]  Anifrolumab Anifrolumab (anifrolumab-fnia) | [1]  Anifrolumab 
                
                    Anifrolumab
                
             (Anifrolumab, Anifrolumab, Anifrolumab-fnia) 💬
 | [2]  IFNAR1 IFNAR1, IFNAR2 💬
 | [18]  Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | [3]  46 46, 49, 53 💬
 | 
| 2 | Anifrolumab (MEDI-546) | [1]  Anifrolumab Anifrolumab (anifrolumab-fnia) | [1]  Anifrolumab 
                
                    Anifrolumab
                
             (Anifrolumab, Anifrolumab, Anifrolumab-fnia) 💬
 | [2]  IFNAR1 IFNAR1, IFNAR2 💬
 | [18]  Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | [1]  46 46 💬
 | 
| 3 | Anifrolumab 1000 mg | [1]  Anifrolumab Anifrolumab (anifrolumab-fnia) | [1]  Anifrolumab 
                
                    Anifrolumab
                
             (Anifrolumab, Anifrolumab, Anifrolumab-fnia) 💬
 | [2]  IFNAR1 IFNAR1, IFNAR2 💬
 | [18]  Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | [1]  49 49 💬
 | 
| 4 | Anifrolumab 300 mg | [1]  Anifrolumab Anifrolumab (anifrolumab-fnia) | [1]  Anifrolumab 
                
                    Anifrolumab
                
             (Anifrolumab, Anifrolumab, Anifrolumab-fnia) 💬
 | [2]  IFNAR1 IFNAR1, IFNAR2 💬
 | [18]  Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | [1]  49 49 💬
 |